Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.

Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study.

Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, Calcagno A, Castelnuovo B.

J Infect Dis. 2020 Feb 28. pii: jiaa088. doi: 10.1093/infdis/jiaa088. [Epub ahead of print]

PMID:
32112093
3.

Dolutegravir-associated hyperglycaemia in patients with HIV.

Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, Kiragga A, Lwanga IB, Castelnuovo B.

Lancet HIV. 2020 Feb 24. pii: S2352-3018(20)30042-4. doi: 10.1016/S2352-3018(20)30042-4. [Epub ahead of print] No abstract available.

PMID:
32105626
4.

Peer distribution of HIV self-test kits to men who have sex with men to identify undiagnosed HIV infection in Uganda: A pilot study.

Okoboi S, Lazarus O, Castelnuovo B, Nanfuka M, Kambugu A, Mujugira A, King R.

PLoS One. 2020 Jan 23;15(1):e0227741. doi: 10.1371/journal.pone.0227741. eCollection 2020.

5.

Implementing routine physical function screening among elderly HIV-positive patients in Uganda.

Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B.

AIDS Care. 2019 Dec 17:1-4. doi: 10.1080/09540121.2019.1703888. [Epub ahead of print]

PMID:
31847531
6.

Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B.

AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x.

7.

Bending the Arc towards Equitable Partnerships in Global Health and Applied Training.

Martin NA, Kalbarczyk A, Nagourney E, Reich A, Hansoti B, Kambugu A, Quinn TC, Manabe YC, Castelnuovo B.

Ann Glob Health. 2019 Nov 6;85(1):130. doi: 10.5334/aogh.2564.

8.

Reasons for first line ART modification over the years during the ART scale up in Uganda.

Castelnuovo B, Mubiru F, Kalule I, Kiragga A.

AIDS Res Ther. 2019 Oct 9;16(1):31. doi: 10.1186/s12981-019-0246-y.

9.

Psychosocial correlates of regular syphilis and HIV screening practices among female sex workers in Uganda: a cross-sectional survey.

Muhindo R, Castelnuovo B, Mujugira A, Parkes-Ratanshi R, Sewankambo NK, Kiguli J, Tumwesigye NM, Nakku-Joloba E.

AIDS Res Ther. 2019 Sep 18;16(1):28. doi: 10.1186/s12981-019-0244-0.

10.

Increasing retention of HIV positive pregnant and breastfeeding mothers on option-b plus by upgrading and providing full time HIV services at a lower health facility in rural Uganda.

Masereka EM, Ngabirano TD, Osingada CP, Wiltshire CS, Castelnuovo B, Kiragga AN.

BMC Public Health. 2019 Jul 15;19(1):950. doi: 10.1186/s12889-019-7280-5.

11.

Sustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in Uganda.

Musaazi J, Sekaggya-Wiltshire C, Kiragga AN, Kalule I, Reynolds SJ, Manabe YC, Castelnuovo B.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):514-521. doi: 10.5588/ijtld.18.0306.

PMID:
31064632
12.

Acceptability, perceived reliability and challenges associated with distributing HIV self-test kits to young MSM in Uganda: a qualitative study.

Okoboi S, Twimukye A, Lazarus O, Castelnuovo B, Agaba C, Immaculate M, Nanfuka M, Kambugu A, King R.

J Int AIDS Soc. 2019 Mar;22(3):e25269. doi: 10.1002/jia2.25269.

13.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

14.

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.

Laker EAO, Nabaggala MS, Kaimal A, Nalwanga D, Castelnuovo B, Musubire A, Kiragga A, Lamorde M, Ratanshi RP.

BMC Infect Dis. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5.

15.

Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics.

Sarfo FS, Castelnuovo B, Fanti I, Feldt T, Incardona F, Kaiser R, Lwanga I, Marrone G, Sonnerborg A, Tufa TB, Zazzi M, De Luca A.

J Infect. 2019 May;78(5):402-408. doi: 10.1016/j.jinf.2019.03.003. Epub 2019 Mar 6.

PMID:
30849438
16.

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.

Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M.

Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.

PMID:
30779340
17.

A decade of antiretroviral therapy in Uganda: what are the emerging causes of death?

Kiragga AN, Mubiru F, Kambugu AD, Kamya MR, Castelnuovo B.

BMC Infect Dis. 2019 Jan 21;19(1):77. doi: 10.1186/s12879-019-3724-x.

18.

Incidence rate of sexually transmitted infections among HIV infected patients on long-term ART in an urban and a rural clinic in Uganda.

Okoboi S, Castelnuovo B, Moore DM, Musaazi J, Kambugu A, Birungi J, Nanfuka M, Van Rie A.

BMC Public Health. 2019 Jan 18;19(1):87. doi: 10.1186/s12889-019-6417-x.

19.

Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA).

Yotebieng M, Brazier E, Addison D, Kimmel AD, Cornell M, Keiser O, Parcesepe AM, Onovo A, Lancaster KE, Castelnuovo B, Murnane PM, Cohen CR, Vreeman RC, Davies MA, Duda SN, Yiannoutsos CT, Bono RS, Agler R, Bernard C, Syvertsen JL, Sinayobye JD, Wikramanayake R, Sohn AH, von Groote PM, Wandeler G, Leroy V, Williams CF, Wools-Kaloustian K, Nash D; IeDEA Treat All in sub-Saharan Africa Consensus Statement Working Group.

J Int AIDS Soc. 2019 Jan;22(1):e25218. doi: 10.1002/jia2.25218.

20.

Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.

Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.

PMID:
30633041
21.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
22.

Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.

Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B.

PLoS One. 2018 Nov 1;13(11):e0206796. doi: 10.1371/journal.pone.0206796. eCollection 2018.

23.

Retention of HIV infected pregnant and breastfeeding women on option B+ in Gomba District, Uganda: a retrospective cohort study.

Kiwanuka G, Kiwanuka N, Muneza F, Nabirye J, Oporia F, Odikro MA, Castelnuovo B, Wanyenze RK.

BMC Infect Dis. 2018 Oct 24;18(1):533. doi: 10.1186/s12879-018-3450-9.

24.

Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda.

Okoboi S, Castelnuovo B, Moore DM, Musaazi J, Kambugu A, Birungi J, Kaleebu P, Nanfuka M, Kamya MR, Van Rie A.

AIDS Res Ther. 2018 Oct 19;15(1):15. doi: 10.1186/s12981-018-0203-1.

25.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
26.

A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients.

Bisaso KR, Karungi SA, Kiragga A, Mukonzo JK, Castelnuovo B.

BMC Med Inform Decis Mak. 2018 Sep 4;18(1):77. doi: 10.1186/s12911-018-0659-x.

27.

Comparison of Löwenstein-Jensen and BACTEC MGIT 960 culture for Mycobacterium tuberculosis in people living with HIV.

Hongler J, Musaazi J, Ledergerber B, Eberhard N, Sekaggya-Wiltshire C, Keller PM, Fehr J, Castelnuovo B.

HIV Med. 2018 Oct;19(9):654-661. doi: 10.1111/hiv.12635. Epub 2018 Jul 3.

PMID:
29971898
28.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

29.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

30.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

31.

Detection of tuberculosis patterns in digital photographs of chest X-ray images using Deep Learning: feasibility study.

Becker AS, Blüthgen C, Phi van VD, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Fehr J, Frauenfelder T.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):328-335. doi: 10.5588/ijtld.17.0520.

PMID:
29471912
32.

Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.

Castelnuovo B, Mubiru F, Kiragga AN, Musomba R, Mbabazi O, Gonza P, Kambugu A, Ratanshi RP.

BMJ Open. 2018 Feb 21;8(2):e015490. doi: 10.1136/bmjopen-2016-015490.

33.

Describing the retention in care of human immunodeficiency virus-positive young adults who transition from adolescent to adult care.

Castelnuovo B, Mubiru F, Nakalema S, Twimukye A, Kiragga A.

Int Health. 2018 Jul 1;10(4):318-320. doi: 10.1093/inthealth/ihx063.

PMID:
29401288
34.

Challenges in Assessing Outcomes among Infants of Pregnant HIV-Positive Women Receiving ART in Uganda.

Castelnuovo B, Mubiru F, Kalule I, Nakalema S, Kiragga A.

AIDS Res Treat. 2017;2017:3202737. doi: 10.1155/2017/3202737. Epub 2017 Dec 7.

35.

Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy.

Flynn AG, Anguzu G, Mubiru F, Kiragga AN, Kamya M, Meya DB, Boulware DR, Kambugu A, Castelnuovo BC.

PLoS One. 2017 Dec 15;12(12):e0189055. doi: 10.1371/journal.pone.0189055. eCollection 2017.

36.

Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis.

Kwizera R, Parkes-Ratanshi R, Page ID, Sekaggya-Wiltshire C, Musaazi J, Fehr J, Castelnuovo B, Kambugu A, Denning DW.

BMC Pulm Med. 2017 Nov 21;17(1):149. doi: 10.1186/s12890-017-0500-9.

37.

A survey of machine learning applications in HIV clinical research and care.

Bisaso KR, Anguzu GT, Karungi SA, Kiragga A, Castelnuovo B.

Comput Biol Med. 2017 Dec 1;91:366-371. doi: 10.1016/j.compbiomed.2017.11.001. Epub 2017 Nov 9. Review.

PMID:
29127902
38.

Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.

Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A.

BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679.

39.

Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.

Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, Kasule J, Serwadda D, Castelnuovo B, Hoog AV, Reynolds SJ.

BMC Infect Dis. 2017 Aug 22;17(1):582. doi: 10.1186/s12879-017-2680-6.

40.

Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial.

Wanyama JN, Nabaggala MS, Wandera B, Kiragga AN, Castelnuovo B, Mambule IK, Nakajubi J, Kambugu AD, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P.

Int J STD AIDS. 2018 Mar;29(3):287-297. doi: 10.1177/0956462417724707. Epub 2017 Aug 17.

PMID:
28814161
41.

Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study.

Musaazi J, Kiragga AN, Castelnuovo B, Kambugu A, Bradley J, Rehman AM.

Public Health Action. 2017 Jun 21;7(2):100-109. doi: 10.5588/pha.16.0115.

42.

Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.

Hermans SM, Babirye JA, Mbabazi O, Kakooza F, Colebunders R, Castelnuovo B, Sekaggya-Wiltshire C, Parkes-Ratanshi R, Manabe YC.

BMC Infect Dis. 2017 Jun 16;17(1):433. doi: 10.1186/s12879-017-2534-2.

43.

Describing Point of Entry into Care and Being Lost to Program in a Cohort of HIV Positive Pregnant Women in a Large Urban Centre in Uganda.

Musomba R, Mubiru F, Nakalema S, Mackline H, Kalule I, Kiragga AN, Ratanshi RP, Castelnuovo B.

AIDS Res Treat. 2017;2017:3527563. doi: 10.1155/2017/3527563. Epub 2017 Apr 2.

44.

Persons living with HIV infection on antiretroviral therapy also consulting traditional healers: a study in three African countries.

Wanyama JN, Tsui S, Kwok C, Wanyenze RK, Denison JA, Koole O, van Praag E, Castelnuovo B, Wabwire-Mangen F, Kwesigabo GP, Colebunders R.

Int J STD AIDS. 2017 Sep;28(10):1018-1027. doi: 10.1177/0956462416685890. Epub 2017 Feb 5.

PMID:
28162034
45.

Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR.

J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.

46.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B.

AIDS Res Ther. 2017 Jan 5;14(1):1. doi: 10.1186/s12981-016-0128-5.

47.

Different modalities of entry in a large urban clinic in Uganda and impact on outcomes of patients assessing HIV care and treatment.

Castelnuovo B, Musomba R, Musaazi J, Kiragga AN.

AIDS Care. 2017 Feb;29(2):259-262. Epub 2016 Aug 15.

PMID:
27684099
48.

Innovative Demand Creation for Voluntary Medical Male Circumcision Targeting a High Impact Male Population: A Pilot Study Engaging Pregnant Women at Antenatal Clinics in Kampala, Uganda.

Semeere AS, Castelnuovo B, Bbaale DS, Kiragga AN, Kigozi J, Muganzi AM, Coutinho AG, Kambugu A.

J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 4:S273-9. doi: 10.1097/QAI.0000000000001041.

49.

First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.

Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ.

J Int AIDS Soc. 2016 Jun 17;19(1):20773. doi: 10.7448/IAS.19.1.20773. eCollection 2016.

50.

Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series.

Sekaggya C, Nalwanga D, Von Braun A, Nakijoba R, Kambugu A, Fehr J, Lamorde M, Castelnuovo B.

BMC Hematol. 2016 Jun 4;16:16. doi: 10.1186/s12878-016-0056-6. eCollection 2016.

Supplemental Content

Loading ...
Support Center